In:
Rheumatology, Termedia Sp. z.o.o., Vol. 59, No. 4 ( 2021-9-2), p. 206-210
Abstract:
Osteoporosis is the most common bone tissue disease and it is characterized by a re�duced bone mineral density (BMD). The main physiopathological mechanisms converge on the un�coupling between bone formation and resorption, thus leading to an enhanced risk of fractures.
Several papers have documented the inverse relationships linking high inflammatory cytokines, anti�citrullinated protein antibodies, rheumatoid factor, and BMD in rheumatoid arthritis (RA). Rituximab (RTX) is a chimeric monoclonal antibody directed against the CD20 receptor of B cells. Since the
Food and Drug Administration approved it for RA in 2006, there have been many clinical experiences regarding its use. Nevertheless, few studies evaluate the effect of rituximab on BMD. RA is a disease
characterized by immune dysfunction with high levels of inflammatory cytokines, autoantibodies, and it is reasonable that a B cell depleting therapy could restore a physiological cytokine balance,
thus exerting an osteoprotective effect on the bone tissue. The purpose of this paper is to highlight any difference in BMD and to assess differences in body composition over a retrospective 18-month
follow-up period after RTX treatment with a B cell depleting therapy. Material and methods We analyzed by dual energy X-ray absorptiometry BMD expressed as g/cm2
and body composition modifications over 18 months with RTX treatment of 20 postmenopausal RA patients. Results After eighteen months of therapy with RTX, a statistically significant increase in vertebral
(L1–L4) BMD and the stability of femoral BMD were documented. Conclusions Rituximab is associated with an improvement of vertebral and preservation of femo�ral BMD, suggesting a bone-sparing effect due to B cell depletion. Furthermore, patients displayed
a redistribution of fat masses toward the hip region.
Type of Medium:
Online Resource
ISSN:
0034-6233
,
2084-9834
DOI:
10.5114/reum.2021.108430
Language:
Unknown
Publisher:
Termedia Sp. z.o.o.
Publication Date:
2021
detail.hit.zdb_id:
2233668-0
Permalink
